Zhitong Finance App News, Shanghai Laishi (002252.SZ) issued an announcement. Recently, the company received the “Notice of Acceptance” issued by the National Drug Administration (NMPA) regarding the SR604 injection novel drug clinical trial (IND) application. The IND application acceptance number is: CXSL2601243. According to the provisions of Article 32 of the “Administrative Licensing Law of the People's Republic of China”, it was decided to accept it after review.

At the same time, the Drug Evaluation Center of the China Drug Administration (“CDE”) issued an announcement. According to the “Rare Disease Innovative Drug Development Encouragement Pilot Program (“Care Plan - Extension”) application guidelines, SR604 injections (proposed indications: “thrombocytopenia” and “prevention and treatment of vascular hemophilia”) will be included in the “Care Plan-Extension” pilot project. The publication period ends on November 10, 2026.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.